🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Alembic Pharmaceuticals Limited APLLTD NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://alembicpharmaceuticals.com
Company Profile ↓
₹828.70
-14.24% 1Y
Mkt Cap₹16,289.19 Cr
P/E24.14
P/B2.88
Div. Yield1.43%
52W High₹1,024.61
52W Low₹646.55
Book Value₹288.70
EPS (TTM)₹34.33

Company Overview

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 25.4% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 10.1% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 24.1, below the sector median of 39.7.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.25.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹7,344.90 Cr (+10.1% YoY); net profit ₹674.77 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +10.1%, earnings +15.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 10.1%, profit CAGR 25.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:10.12%
1 Year:10.08%

Compounded Profit Growth

5 Years:25.42%
1 Year:15.66%

Stock Price Performance

1 Year:-14.24%
6 Months:+3.59%
3 Months:+10.74%
1 Month:+12.33%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 48% of range
₹646.55 ₹1,024.61
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)63.03 · Neutral
Price Performance
1M+12.33%
3M+10.74%
6M+3.59%
1Y-14.24%
Valuation vs Sector

P/E of 24.14 is below the sector median of 39.70 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 10.1% over 5 years.
  • Profit CAGR of 25.4% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
24.14
Industry PE
39.70
Forward P/E
17.27
PEG Ratio
-
Book Value
₹288.70
Price to Book
2.88
P/S
2.22
EV/EBITDA
15.70
Dividend Yield
1.43%

Growth (CAGR)

Revenue 5Y
10.12%
Profit 5Y
25.42%
Revenue (YoY)
10.08%
Earnings (YoY)
15.66%

Profitability & Returns

ROCE
12.77%
ROE
11.89%
ROA
7.70%
Profit Margin
9.19%
Op Margin
10.89%
Gross Margin
72.98%
EPS (Latest Qtr)
₹10.31
EPS (TTM)
₹34.33

Balance Sheet & Liquidity

Debt/Equity
0.25
Quick Ratio
0.79
Current Ratio
1.76
Debt
₹1,429.94 Cr
Total Assets
₹8,762.59 Cr
Current Assets
₹4,572.59 Cr
Working Capital
₹1,978.75 Cr

Ownership

Promoter Holding
70.70%
Chg in Prom Hold
0.05%
FII / Inst Holding
17.24%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹16,289.19 Cr
Total Revenue (TTM)
₹7,344.90 Cr
EBITDA
₹1,106.13 Cr
Free Cash Flow
₹287.85 Cr
Operating Cash Flow
₹782.73 Cr
Shares Outstanding
₹19.66 Cr
Gross Margin
72.98%
Payout Ratio
32.04%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 APLLTD Alembic Pharmaceuticals Limited NSEPHARMA 828.70 24.14 ₹16,289.19 Cr 1.43% 12.77% 11.89% 10.12% 25.42%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 1,406.00 Cr1,486.00 Cr1,595.00 Cr1,631.00 Cr1,517.00 Cr1,562.00 Cr1,648.00 Cr1,692.74 Cr1,769.64 Cr1,710.72 Cr1,910.00 Cr1,876.31 Cr1,847.72 Cr
Cost of Revenue -------439.54 Cr530.61 Cr407.41 Cr-528.97 Cr532.15 Cr
Gross Profit -------1,253.20 Cr1,239.03 Cr1,303.31 Cr-1,347.34 Cr1,315.57 Cr
Operating Expenses 1,203.00 Cr1,287.00 Cr1,387.00 Cr1,364.00 Cr1,257.00 Cr1,325.00 Cr1,409.00 Cr1,063.02 Cr1,036.09 Cr1,095.73 Cr1,594.00 Cr1,133.96 Cr1,176.24 Cr
Operating Income 130.00 Cr133.00 Cr140.00 Cr197.00 Cr191.00 Cr168.00 Cr168.00 Cr190.18 Cr202.94 Cr207.58 Cr240.00 Cr213.38 Cr139.33 Cr
EBITDA 204.00 Cr199.00 Cr208.00 Cr266.00 Cr260.00 Cr237.00 Cr239.00 Cr270.08 Cr285.46 Cr287.39 Cr316.00 Cr264.93 Cr229.77 Cr
Interest Expense 14.00 Cr14.00 Cr16.00 Cr15.00 Cr11.00 Cr13.00 Cr19.00 Cr22.26 Cr24.52 Cr23.52 Cr24.00 Cr23.31 Cr22.56 Cr
Pretax Income 116.00 Cr130.00 Cr135.00 Cr185.00 Cr183.00 Cr157.00 Cr180.00 Cr177.78 Cr191.95 Cr190.10 Cr224.00 Cr161.50 Cr118.62 Cr
Tax Provision -35.96 Cr9.10 Cr-1.35 Cr3.70 Cr5.49 Cr21.98 Cr27.00 Cr40.08 Cr35.31 Cr36.48 Cr40.32 Cr29.54 Cr-82.91 Cr
Net Income 153.00 Cr121.00 Cr137.00 Cr180.00 Cr178.00 Cr135.00 Cr153.00 Cr138.42 Cr156.89 Cr154.38 Cr184.00 Cr132.97 Cr202.70 Cr
Diluted EPS 7.766.146.959.189.076.857.807.017.987.859.406.7610.31

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 2,056.00 Cr3,166.00 Cr3,105.00 Cr3,131.00 Cr3,935.00 Cr4,606.00 Cr5,393.00 Cr-5,499.77 Cr6,112.11 Cr6,672.08 Cr7,344.90 Cr
Cost of Revenue --------2,023.16 Cr2,000.70 Cr1,793.36 Cr1,984.45 Cr
Gross Profit --------3,476.61 Cr4,111.41 Cr4,878.72 Cr5,360.45 Cr
Operating Expenses 1,653.00 Cr2,159.00 Cr2,490.00 Cr2,488.00 Cr3,061.00 Cr3,383.00 Cr3,913.00 Cr-3,032.53 Cr3,447.87 Cr4,149.07 Cr4,560.54 Cr
Operating Income 359.00 Cr935.00 Cr532.00 Cr538.00 Cr759.00 Cr1,066.00 Cr1,297.00 Cr-444.08 Cr663.54 Cr729.65 Cr799.91 Cr
EBITDA 403.00 Cr1,007.00 Cr615.00 Cr643.00 Cr874.00 Cr1,223.00 Cr1,480.00 Cr-680.19 Cr960.69 Cr1,064.53 Cr1,106.13 Cr
Interest Expense 4.00 Cr5.00 Cr5.00 Cr3.00 Cr18.00 Cr27.00 Cr16.00 Cr-50.17 Cr56.19 Cr78.77 Cr93.63 Cr
Pretax Income 359.00 Cr936.00 Cr529.00 Cr541.00 Cr749.00 Cr1,000.00 Cr1,368.00 Cr-354.59 Cr631.83 Cr707.18 Cr693.95 Cr
Tax Provision 75.39 Cr215.28 Cr121.67 Cr119.02 Cr157.29 Cr200.00 Cr259.92 Cr-12.61 Cr16.00 Cr125.17 Cr23.12 Cr
Net Income 283.00 Cr720.00 Cr403.00 Cr413.00 Cr583.00 Cr801.00 Cr1,146.00 Cr-341.99 Cr615.82 Cr583.42 Cr674.77 Cr
Diluted EPS 15.0138.2021.3921.8931.0043.9758.33-17.4031.3329.6834.33

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 1,641.00 Cr2,429.00 Cr2,689.00 Cr3,941.00 Cr4,778.00 Cr5,989.00 Cr6,709.00 Cr-6,182.83 Cr6,445.58 Cr7,772.94 Cr8,762.59 Cr
Current Assets --------2,910.02 Cr3,078.56 Cr4,087.79 Cr4,572.59 Cr
Cash & Equivalents --------75.48 Cr120.21 Cr83.48 Cr196.37 Cr
Inventory --------1,475.27 Cr1,643.54 Cr2,288.14 Cr2,510.64 Cr
Receivables --------1,046.40 Cr1,024.84 Cr1,399.79 Cr1,466.30 Cr
Total Liabilities --------1,812.37 Cr1,627.38 Cr2,583.42 Cr3,093.61 Cr
Current Liabilities --------1,636.92 Cr1,455.00 Cr2,412.34 Cr2,593.84 Cr
Long Term Debt -------0---121.92 Cr
Total Debt 264.00 Cr114.00 Cr89.00 Cr708.00 Cr1,128.00 Cr1,747.00 Cr584.00 Cr-722.01 Cr513.16 Cr1,257.50 Cr1,429.94 Cr
Total Equity 885.00 Cr1,598.00 Cr1,903.00 Cr2,220.00 Cr2,719.00 Cr3,220.00 Cr5,067.00 Cr-4,370.46 Cr4,818.20 Cr5,190.94 Cr5,674.81 Cr
Shares Outstanding --------19.66 Cr19.66 Cr19.66 Cr19.66 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 172.00 Cr948.00 Cr329.00 Cr312.00 Cr812.00 Cr449.00 Cr1,463.00 Cr-723.95 Cr803.20 Cr87.97 Cr782.73 Cr
Investing Cash Flow -256.00 Cr-307.00 Cr-486.00 Cr-884.00 Cr-756.00 Cr-731.00 Cr-840.00 Cr--447.59 Cr-320.61 Cr-568.41 Cr-506.06 Cr
Financing Cash Flow 87.00 Cr-224.00 Cr-129.00 Cr503.00 Cr59.00 Cr155.00 Cr-597.00 Cr--261.96 Cr-437.87 Cr443.71 Cr-163.79 Cr
Capital Expenditure -224.00 Cr-301.00 Cr19.00 Cr-807.00 Cr-763.00 Cr-734.00 Cr-659.00 Cr--443.41 Cr-327.47 Cr-563.62 Cr-494.88 Cr
Free Cash Flow -52.00 Cr647.00 Cr348.00 Cr-495.00 Cr49.00 Cr-285.00 Cr804.00 Cr-280.54 Cr475.73 Cr-475.65 Cr287.85 Cr
Net Change in Cash 3.00 Cr417.00 Cr-286.00 Cr-69.00 Cr115.00 Cr-127.00 Cr26.00 Cr-14.40 Cr44.72 Cr-36.73 Cr112.88 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------63.2%67.3%73.1%73.0%
Operating Margin % 17.5%29.5%17.1%17.2%19.3%23.1%24.0%-8.1%10.9%10.9%10.9%
Net Margin % 13.8%22.7%13.0%13.2%14.8%17.4%21.2%-6.2%10.1%8.7%9.2%
ROE % 32.0%45.1%21.2%18.6%21.4%24.9%22.6%-7.8%12.8%11.2%11.9%
ROCE % --------9.8%13.3%13.6%13.0%

Shareholding Pattern

Insiders
70.70%
Institutions
17.24%
Public Float
58.84%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for APLLTD

Yahoo Finance Fri, 15 May 2026

Alembic Pharmaceuticals Ltd (BOM:533573) Q4 2026 Earnings Call Highlights: Steady Growth Amidst ...

Alembic Pharmaceuticals Ltd (BOM:533573) reports a 4% revenue increase and strategic advancements despite ongoing pricing pressures and supply chain volatility.

Yahoo Finance Mon, 09 Feb 2026

Alembic Pharmaceuticals Ltd (BOM:533573) Q3 2026 Earnings Call Highlights: Strong Revenue ...

Alembic Pharmaceuticals Ltd (BOM:533573) reports an 11% revenue increase, driven by strategic expansions and new product launches, despite facing pricing challenges and margin contractions.

Yahoo Finance ue, 04 Nov 2025

Alembic Pharmaceuticals Ltd (BOM:533573) Q2 2026 Earnings Call Highlights: Strong Revenue ...

Alembic Pharmaceuticals Ltd (BOM:533573) reports robust international growth and strategic acquisitions, despite facing pricing pressures and increased R&D expenses.

APLLTD — Frequently Asked Questions

What is the current share price of Alembic Pharmaceuticals Limited (APLLTD)?

As of 2026-07-16 05:21 IST, Alembic Pharmaceuticals Limited (APLLTD) trades at ₹828.70 on NSE. Its 52-week range is ₹646.55 to ₹1,024.61.

What is the market capitalisation of APLLTD?

Alembic Pharmaceuticals Limited (APLLTD) has a market capitalisation of ₹16,289.19 Cr on NSE.

What is the P/E ratio of APLLTD?

APLLTD trades at a trailing price-to-earnings (P/E) ratio of 24.14. The industry average P/E is 39.70. Its price-to-book (P/B) ratio is 2.88.

Does APLLTD pay a dividend?

Alembic Pharmaceuticals Limited (APLLTD) currently offers a dividend yield of 1.43%.

What is the return on equity (ROE) of APLLTD?

APLLTD has a return on equity (ROE) of 11.89%. Its return on capital employed (ROCE) is 12.77%.

Is APLLTD a good stock to buy?

This page provides a data-driven analysis of Alembic Pharmaceuticals Limited (APLLTD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space